Key facts
- Solence’s last known valuation is $6.9M (Jul 2025).
- It has raised $2.1M; the latest was Seed Round ($1.9M) in Jul 2025.
- Notable investors include Bpifrance, Celine Lazorthes, Berthe Latreille, Impact Shakers, Impact Shakers Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Solence
- ·The full record, as it builds
Funding rounds
No funding rounds for Solence are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Solence
Developer of a digital health support tool designed to manage chronic hormonal conditions. The company offers a personalized program that combines educational content, lifestyle tracking, symptom monitoring, and behavioral guidance of polycystic ovary syndrome, enabling women to better understand and manage their condition through structured routines and habit-building strategies.
- Sector
- Healthcare
- HQ
- Strasbourg, France
- Founded
- 2022
- Employees
- 8
- Website
- solence.care/
- Ownership
- Privately Held (backing)
Solence doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Solence shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Solence in its N-PORT filings yet. We sweep new filings monthly.